- NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
- NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
- NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
- NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
- NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
- NeuroPace Reports Third Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
- NeuroPace Announces RNS System Enhancements Designed to Streamline Care
- NeuroPace to Report Third Quarter 2023 Financial Results on November 6, 2023
- NeuroPace to Participate in 2023 Cantor Fitzgerald Global Healthcare Conference
More ▼
Key statistics
On Wednesday, Neuropace Inc (NPCE:NMQ) closed at 7.24, 85.17% above the 52 week low of 3.91 set on Jul 25, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.25 |
---|---|
High | 7.45 |
Low | 7.09 |
Bid | 5.75 |
Offer | 9.00 |
Previous close | 7.23 |
Average volume | 283.05k |
---|---|
Shares outstanding | 28.77m |
Free float | 23.11m |
P/E (TTM) | -- |
Market cap | 208.28m USD |
EPS (TTM) | -1.18 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼